Dr. Thomas Marron, MD PhD
Claim this profileIcahn School of Medicine at Mount Sinai
Studies Lung Cancer
Studies Solid Tumors
14 reported clinical trials
24 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
RECIST 1.1
2Solid Tumors
Stage IV
Stage III
FGFR2 positive
Affiliated Hospitals
Clinical Trials Thomas Marron, MD PhD is currently running
Lamivudine
for Solid Tumors
Single arm, set dose clinical trial of Lamivudine for Relapsed Refractory Solid Tumors. Accrual 6-24 patients, within 2 years, study completion within 3 years at Mount Sinai Health System. Primary Objective: For Phase 1b to determine the safety and tolerability of Lamivudine with continued PD-(L)1 blockade for patients with relapsed/refractory metastatic solid tumors that have progressed on standard PD-(L)1 blockade. For Phase 2, to determine the effect of adding lamivudine to PD-(L)1 blocking agents in patients with relapsed/refractory solid tumors that have progressed on prior PD-(L)1 agents Secondary Objectives (Phase 1b and 2) Assess 1) Safety and Tolerability, 2) Best overall response rate (BORR), 3) Progression-free survival (PFS), 4) Overall survival (OS) and 5) Duration of response following addition of lamivudine to standard PD-(L)1 blocking agents, 6) Disease control rate (DCR).
Recruiting1 award Phase 1 & 24 criteria
Voyager V1 + Cemiplimab
for Melanoma
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Recruiting1 award Phase 2
More about Thomas Marron, MD PhD
Clinical Trial Related1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Thomas Marron, MD PhD has experience with
- Pembrolizumab
- Dupilumab
- Cemiplimab
- Nivolumab
- BMS-986253
- Botensilimab
Breakdown of trials Thomas Marron, MD PhD has run
Lung Cancer
Solid Tumors
Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Thomas Marron, MD PhD specialize in?
Thomas Marron, MD PhD focuses on Lung Cancer and Solid Tumors. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Thomas Marron, MD PhD currently recruiting for clinical trials?
Yes, Thomas Marron, MD PhD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Thomas Marron, MD PhD has studied deeply?
Yes, Thomas Marron, MD PhD has studied treatments such as Pembrolizumab, Dupilumab, Cemiplimab.
What is the best way to schedule an appointment with Thomas Marron, MD PhD?
Apply for one of the trials that Thomas Marron, MD PhD is conducting.
What is the office address of Thomas Marron, MD PhD?
The office of Thomas Marron, MD PhD is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.